Adverse Event Following Immunization (AEFI) in Children: An Analysis
                    of Reporting in VigiAccess

Diksha Pandey; Geetika Mehta; Monika Sachdeva; Rashmi Tripathi

doi:10.1055/a-1852-5335

Drug Research, Inhaltsverzeichnis

Drug Res (Stuttg) 2022; 72(08): 435-440
DOI: 10.1055/a-1852-5335

Original Article

Adverse Event Following Immunization (AEFI) in Children: An Analysis of Reporting in VigiAccess

Diksha Pandey

¹Department of Pharmacology, Raj Kumar Goel Institute of Technology (Pharmacy), Ghaziabad, Uttar Pradesh, India

,

Geetika Mehta

¹Department of Pharmacology, Raj Kumar Goel Institute of Technology (Pharmacy), Ghaziabad, Uttar Pradesh, India

,

Monika Sachdeva

¹Department of Pharmacology, Raj Kumar Goel Institute of Technology (Pharmacy), Ghaziabad, Uttar Pradesh, India

,

Rashmi Tripathi

¹Department of Pharmacology, Raj Kumar Goel Institute of Technology (Pharmacy), Ghaziabad, Uttar Pradesh, India

› Institutsangaben

Abstract

Introduction It is an indubitable fact that vaccination has been instrumental in the eradication and prevention of the deadliest diseases worldwide. Continuous vaccine safety surveillance is helpful to counter the negative perception and thus allay the fear of Adverse Events Following Immunization (AEFI) in the general public. VigiAccess, the WHO global database of reported side effects of medicinal products, can be accessed by the public at large. The objective of this study is to assess the characteristics of AEFIs of the commonly used vaccines in children in VigiAccess.

Materials and Methods VigiAccess was thoroughly explored for the categories, number, and types of AEFIs of commonly used vaccines among children that are reported in five continents between 2011 and 2021.

Results After a comprehensive analysis in VigiAccess, 27 kinds of AEFIs were discovered. For the nine vaccines, a total of 1,412,339 AEFIs were found. The most prevalent AEFIs were general disorder and administration site condition (436,199 or 30%). The majority of AEFIs are found in America, with Europe, Oceania, Asia, and Africa following closely behind. Girls of age from 27 days to 23 months had the highest number of AEFIs. The highest number of AEFIs was recorded in the year 2018.

Conclusion America has the maximum, whilst Africa has the least AEFI. Few AEFIs were caused by the measles vaccination, while the majority were related to the general disorder and administration site condition. Data synchronization in VigiAccess needs to be enhanced to improve its dependability.

Key words

Adverse reactions - VigiAccess - pharmacovigilance - adverse event following immunization

Volltext

Referenzen

References
1 Global Manual on Surveillance of AEFI – WHO https://www.who.int/vaccine_safety/publications/Global_Manual_on_Surveillance_of_AEFI.pdf
2 Izurieta HS, Zuber P, Bonhoeffer J. et al. Roadmap for the international collaborative epidemiologic monitoring of safety and effectiveness of new high priority vaccines. Vaccine 2013; 31: 3623-3627
3 Shimabukuro TT, Nguyen M, Martin D. et al. Safety monitoring in the vaccine adverse event reporting system (VAERS). Vaccine 2015; 33: 4398-4405
4 Vaccine Safety E-Course Manual – World Health Organization https://www.who.int/vaccine_safety/initiative/tech_support/Vaccine-safety-E-course-manual.pdf
5 WHO: Causality assessment of an adverse event following immunization (AEFI): user manual for the revised WHO classification (Second edition). 2nd Edition Geneva: World Health Organization; 2018
6 Cashman P, Macartney K, Khandaker G. et al. Participant-centered active surveillance of adverse events following immunization: a narrative review. Int. Health 2017; 9: 164-176
7 Parrella A, Gold M, Braunack MA. et al. Consumer reporting of adverse events following immunization (AEFI) Identifying predictors of reporting an AEFI. Hum Vaccin Immunother 2014; 10: 747-754
8 Hu Y, Li Q, Lin L. et al. Surveillance for adverse events following immunization from 2008 to 2011 in Zhejiang Province, China. Clin Vaccine Immunol 2013; 20: 211-217
9 Clothier HJ, Selvaraj G, Easton ML. et al. Consumer reporting of adverse events following immunization. Hum. Vaccin Immunother. 2014; 10: 3726-3730
10 Parrella A, Braunack-Mayer A, Gold M. et al. Healthcare providers’ knowledge, experience and challenges of reporting adverse events following immunisation: a qualitative study. BMC Health Serv. Res 2013; 13: 1-12
11 Hazell L, Cornelius V, Hannaford P. et al. Yellow card study collaboration how does patients contribute to signal detection? A retrospective analysis of spontaneous reporting of adverse drug reactions in the UK’s yellow card scheme. Drug Safety 2013; 36: 199-206
12 Inch J, Watson MC, Anakwe US. Patient versus healthcare professional spontaneous adverse drug reaction reporting. Drug safety 2012; 35: 807-818
13 Ampadu HH, Hoekman J, Bruin ML. et al. Adverse drug reaction reporting in Africa and a comparison of individual case safety report characteristics between Africa and the rest of the world: analyses of spontaneous reports in VigiBase^® . Drug Safety 2016; 39: 335-345
14 Linquist M. VigiBase, the WHO Global ICSR Database System. Basic Facts. Drug Inf. J 2008; 42: 409-419
15 Yadav S. (2008). Status of adverse drug reaction monitoring and pharmacovigilance in selected countries. Indian J. Pharmacol 2008; 40: S4-S9
16 Shankar PR. VigiAccess: Promoting public access to VigiBase. Indian J. Pharmacol 2016; 48: 606
17 Yamoah POF, Oosthuizen F. An assessment of the reporting pattern of adverse events following immunisations in VigiAccess. Global J Health Sci 2018; 10: 46-56
18 Centers for Disease Control and Prevention. Vaccines and preventable diseases. 2018
19 Definitions and Applications of Terms for Vaccine. CIOMS https://cioms.ch/publications/product/definitions-and-applications-of-terms-for-vaccine-pharmacovigilance/
20 Lawrence GL, Aratchige PE, Boyd I. et al. Annual report on surveillance of adverse events following immunization in Australia, 2006. Commun Dis Intell Q Rep 2007; 31: 269-282
21 Williams SE, Edwards KM, Baxter RP. et al. Comprehensive assessment of serious adverse events following immunization by health care providers. J Pediatr 2013; 162: 1276-1281
22 Miravalle A, Biller J, Schnitzler E. et al. Neurological complications following vaccinations. Neurol. Res. 2010; 32: 285-292
23 Williams SE, Pahud BA, Vellozzi C. et al. Causality assessment of serious neurologic adverse events following 2009 H1N1 vaccination. Vaccine 2011; 29: 8302-8308
24 Moretti F, Gonella L, Gironi S. Ten years of vaccinovigilance in Italy: an overview of the pharmacovigilance data from 2008 to 2017. Sci Rep 2020; 10: 14122
25 Lussier N, Bourgault AM, Gaudreau C. et al. A complication of BCG vaccine: A case of localized cutaneous abscess due to Mycobacterium bovis. Can J Infect Dis 1999; 10: 257-259
26 Crum-Cianflone NancyF, Mark RWallace. “Vaccination in HIV-infected adults.”. AIDS patient care and STDs 2014; 28: 397-410
27 Lei J, Balakrishnan MR, Gidudu JF. et al. Use of a new global indicator for vaccine safety surveillance and trends in adverse events following immunization reporting 2000-2015. Vaccine. 2018; 36: 1577-1582
28 Masuka JT, Khoza S. Adverse events following immunisation (AEFI) reports from the Zimbabwe expanded programme on immunisation (ZEPI): an analysis of spontaneous reports in Vigibase® from 1997 to 2017. BMC Public Health 2019; 19: 1166
29 World Health Organization [WHO]. (2016). Global vaccine action plan, Secretariat annual report 2016. Retrieved from http://www.who.int/immunization/global_vaccine_action_plan/gvap_secretariat_report_2016.pdf?ua=1
30 Hardt K, Schmidt-Ott R, Glismann S. et al. Sustaining vaccine confidence in the 21st century. Vaccines 2013; 1: 204-224
31 “VigiAccess.” http://vigiaccess.org/